Clinical Outcomes Following Supply‐Driven Transition From Intranasal to Oral Desmopressin in AVP‐Deficiency—A Single Centre Experience Including The Pituitary Foundation Desmopressin Shortage Impact Report

45.2% (19/42) of patients achieved adequate symptom control post-switch with varying conversion ratios, and over half (13/23, 56.5%) of patients switched with an initial 1:10 conversion ratio reported symptomatic recurrence. Although a higher initial conversion ratio closer to 1:15 may reduce symptomatic recurrence in some patients, initiating treatment at a 1:10 ratio with careful up-titration represents a safe and pragmatic approach that minimises the risk of over-replacement and hyponatraemia, although inter-patient variability necessitates tailored titration. In parallel, national patient-reported data from The Pituitary Foundation Impact Report demonstrate the substantial patient and clinical burden of this supply-driven switch, highlighting the need for standardised guidance and prospective studies.